Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.41%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (1.19%) 5:34 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
APTO 0.67 -0.03(-4.41%)
Will APTO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APTO
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Aptose Biosciences (APTO) a New Buy Stock
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Other News for APTO
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Biosciences Shareholders Approve Key Proposals
Tuspetinib: A Promising Candidate for Enhancing r/r AML Treatment Outcomes
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences Issues Non-Filed Information Disclosure